Page 34 - Demo

Chapter 232first. TTP is further described in this study as PFS. Measurements of CA19.9 (U/mL) were performed before and during treatment. CA19.9 response was defined as a decrease in CA19.9 concentration of at least 50% from the baseline concentration to the lowest value (nadir) measured during the study. Results Patient characteristics Twenty patients were registered in this study. Five patients were considered ineligible, because of either metastatic disease (n = 3), elevated liver enzymes (n = 1), and patient withdrawal before start of treatment (n = 1). Between July 2010 and November 2013, treatment was initiated in 15 patients. One patient in the 1.5 mg/kg cohort withdrew her consent after 2 weeks and was therefore considered not evaluable. The clinicopathologic characteristics of the 14 treated patients are listed in Table 1. Table 1. Clinicopathologic characteristics for 14 patients receiving chemoradiation with panitumumab for LAPCCharacteristicPatients, n(N =14) %Age (years at the start of the treatment) 63 (46%u201377)SexMale 11 79Female 3 21Histology/cytology Adenocarcinoma Other: neuro-endocrine tumor131937Diagnosis based on CytologyHistology410T-stageT3 1 7T4 13 93N stageN0 14 100N1 0 0ECOG PS at start0 9 641 5 36Ca19,9 prior to therapy, U/mLMedian 103Range 5%u20131,499